Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23 | Direct | 30,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001952533-26-000002 · form4-06262026_040612.xml · derivative · entry 1 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001415889-25-018388 · form4-06272025_040614.xml · derivative · entry 1 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001415889-24-018012 · form4-06242024_050607.xml · derivative · entry 1 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 01:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-040113 · doc4.xml · derivative · entry 1 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (Right to Buy) · Derivative | 118,190 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001209191-22-056440 · doc4.xml · derivative · entry 3 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,190 Underlying: Common Stock · 118,190 shares Expires 2031-12-13 F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F7 · price: Received in exchange for a stock option to acquire 100,000 shares of common stock of ARS pursuant to the Merger Agreement. F6 · derivative.exercise_date: The shares vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (right to buy) · Derivative | 70,422 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056440 · doc4.xml · derivative · entry 2 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,422 Underlying: Common Stock · 70,422 shares Expires 2029-07-04 F4 · price: Received in exchange for a stock option to acquire 59,584 shares of common stock of ARS pursuant to the Merger Agreement. F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 83,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056440 · doc4.xml · nonDerivative · entry 1 Kelly Michael · CIK 0001952533 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The 2019 Michael Kelly Irrevocable Deed of Trust Disclosed balance after: 83,225 F1 · price: Received in exchange for 70,416 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F2 · ownership.nature: The Reporting Person's spouse and sister are trustees of the trust. The beneficiary of the trust is the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these Securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.